

# Krungsri China Megatrends fund-A

(KFCMEGA-A)

**IPO: 7 – 15 June 2021** 

This mutual fund concentrates its investment in Consumer Discretionary Sector. Therefore, the investors may incur a substantial loss of investment.

# **Krungsri China Megatrends fund-A (KFCMEGA-A)**

Get access to the five's China megatrends in one fund







#### China today is far out in front of the world in terms of overall e-commerce sales

Top 10 Countries ranked by retail e-commerce sales, 2020 & 2021


| Country        | 2020 (Billion USD) | 2021 (Billion USD) | % change |
|----------------|--------------------|--------------------|----------|
| 1. China       | 2,296.95           | 2,779.31           | 21.0%    |
| 2. US          | 794.50             | 843.15             | 6.1%     |
| 3. UK          | 180.39             | 169.02             | -6.3%    |
| 4. Japan       | 141.26             | 144.08             | 2.0%     |
| 5. South Korea | 110.60             | 120.56             | 9.0%     |
| 6. Germany     | 96.86              | 101.51             | 4.8%     |
| 7. France      | 73.80              | 80.00              | 8.4%     |
| 8. India       | 55.35              | 67.53              | 22.0%    |
| 9. Canada      | 39.22              | 44.12              | 12.5%    |
| 10. Spain      | 36.40              | 37.12              | 2.0%     |

Source: eMarketer, Dec 2020. Note: includes products or services ordered using the internet via any device, regardless of the method of payment or fulfillment; excludes travel and event tickets, payments such as bill pay, taxes or money transfers, food services and drinking place sales, gambling and other vice good sales. \*excludes Hong Kong






# 52.1% of the country's retail sales will come from e-commerce in 2021



Source: eMarketer, Dec 2020. Note: includes products or services ordered using the internet via any device, regardless of the method of payment or fulfillment; excludes travel and event tickets, payments such as bill pay, taxes or money transfers, food services and drinking place sales, gambling and other vice good sales; excludes Hong Kong





Source: eMarketer, Dec 2020. Note: includes products or services ordered using the internet via any device, regardless of the method of payment or fulfillment; excludes travel and event tickets, payments such as bill pay, taxes or money transfers, food services and drinking place sales, gambling and other vice good sales.

**Denmark Norway** 

US

**Finland** 

Sweden

France

Spain

UK

Remark: Please study fund features, performance, and risk before investing. Past performance is not an indicative of future performance.




China !

South

Korea





# Chinese e-commerce companies have substantial revenue growth



1Y Growth 73%

5Y Growth 729%



1Y Growth 31%

**5Y Growth 47%** 



1Y Growth 28%


5Y Growth 34%

Source: Bloomberg, KraneShares as of 31 Dec 2020.





## China now has nearly 1 billion internet users



Source: CNNIC, Jun 2020.





## Revenue growth rates for China internet companies are higher than U.S.







Source: Bloomberg, KraneShares as of 31 Dec 2020





# Chinese uses internet for messaging, search and online shopping & payment





Source: CNNIC, Jun 2020.






## An aging population means a growing health care market


China's aging population is expected to increase the burden of chronic disease by 40% by 2030<sup>1</sup>

China's healthcare expenditure is still small compared to the US<sup>2</sup>

Population aged 65 or older as % of total population<sup>3</sup>

Healthcare expenditure as % of GDP






#### Source: KraneShares

- 1. Data from the National Bureau of Statistics of China. Data as of 31 Dec 2017. Retrieved 31 Dec 2020.
- 2. Data from the World Health Organization as of 31 Dec 2017, last updated on 7 Apr 2020. Retrieved 31 Dec 2020.
- 3. Data from the World Bank as of 31 Dec 2019. Retrieved 31 Dec 2020.





#### China is one of the fastest growing major healthcare markets in the world




Source: The World Health Organization as of 31 Dec 2017, last updated on 7 Apr 2020. Retrieved 31 Mar 2021






## China has continued to break historical pharmaceutical sales records

- China's pharmaceutical sales is projected to grow substantially in the future<sup>1</sup>
- China's pharmaceutical sales Per capita health spending remains low<sup>2</sup>
- ☐ In 2011, China adopted Universal Healthcare with 95% of China's population gaining access to healthcare services<sup>3</sup>





#### Source: KraneShares.

- 1. China Daily. "Fast growth in China's pharmaceutical market to benefit foreign firms." 29 Sep 2019. Retrieved on 31 Dec 2020. Number is according to healthcare information company, IQVIA
- 2. Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 31 Dec 2020.
- 3. Sun et al., "Chinese healthcare system and clinical epidemiology", NIH, 16 Mar 2017.
- 4. IMS Market Prognosis, 2018. Retrieved on 31 Dec 2020.





# ? Did you know?

Average drug costs on comparable developments<sup>2</sup>


**US:** \$3,000 - \$4,000 M


China: \$30 - \$40 M

# China offers a favorable environment for drug research and development

Favorable policies: In 2015, the China Food and Drug

Administration (CFDA) set policies aimed towards:





Source: KraneShares.

- 1. BCG, "The Next Decade of Opportunity and Jeopardy in China's Pharma Market", Jan 2019
- 2. Fortune, "Why China is Having A Healthcare Boom", 18 Jan 2018. Retrieved 31 Dec 2020





# **Energy Transition Investment Trend**

\$501.3bn

Global energy transition investment in 2020


9%

YoY increase in 2020, happening despite Covid-19

2%

YoY growth in renewable investment, specifically

## Global investment in energy transition by sector




Source: BloombergNEF





## China invested more than any other country




Source: BloombergNEF





# China has outpaced other world leaders in its expansion of electric power capacity from renewable technologies



Source: Data from REN21's Renewables 2020 Global Status Report (GSR) p.205 as of 31 Dec 2019, retrieved on 31 Dec 2020.





Per capita renewable power output, China produces less than half the capacity of the US, and 1/3 the capacity of the European union

# While China is the world leader in renewable energy, there is still significant room for growth

|         | Per capita capacity                                  | China's 2019 Globa | al Rank in Power Ca | apacity |
|---------|------------------------------------------------------|--------------------|---------------------|---------|
|         | (kilowatts per inhabitant, not including hydropower) | 1                  | Wind Power          | 1st     |
| Global  | 0.2                                                  |                    |                     |         |
| BRICS   | 0.2                                                  | ~                  | Hydropower          | 1st     |
| EU-28   | 0.7                                                  | $\sim$             | .,,,                | 150     |
| China   | 0.3                                                  |                    | Solar Power         | 1st     |
| USA     | 0.6                                                  | 200                | Solar Fower         | 150     |
| India   | 0.1                                                  |                    | Bio Power           | 1st     |
| Germany | 1.4                                                  | ~                  | DIO I OWEI          | 151     |
| Japan   | 0.4                                                  | 2)                 | Geothermal          |         |
| UK      | 0.7                                                  | O                  | Power               | 3rd     |

Source: Data from REN21's Renewables 2020 Global Status Report (GSR) p.205 as of 31 Dec 2019, retrieved on 31 Dec 2020.






## China has been a global leader in electric vehicle adoption

China is set for a sustained period of strong EV growth. Canalys forecasts 51% EV growth in China in 2021. EVs will represent one third of car sales in 2025

China passenger car sales\*




Source: Canalys estimates, Jan 2021. \*excludes commercial vehicles





#### China is the largest automobile market in the world

Auto sales (million): China and U.S.



Source: Bloomberg



# Investment strategy







# Global X MSCI China Consumer Discretionary ETF

A targeted play on the Consumer Discretionary Sector in China – the world's second largest economy by GDP

Get access to the five's China megatrends in one fund



Invesco China Technology ETF

Mainly invests in China technology companies globally including A-shares, H-shares and ADRs



**KraneShares MSCI China Clean Technology Index ETF** 

Invests in Clean Technology themes: Alternative Energy, Sustainable Water, Green Building, Pollution Prevention and Energy Efficiency



KraneShares MSCI All China Health Care Index ETF

Invests in Chinese companies that are involved in the healthcare industry



# Portfolio allocation 10% 20% 50%

■ Global X MSCI China Consumer Discretionary ETF

20%


- Invesco China Technology ETF
- KraneShares MSCI China Clean Technology Index ETF
- KraneShares MSCI All China Health Care Index ETF

## **Referenced benchmark**

Portfolio allocation is constructed with reference to sector weighting in MSCI China All shares index.

#### **MSCI China All Shares**

#### SECTOR WEIGHTS



Source: MSCI. Portfolio allocation is just an indicative which is subjective to change based on market conditions.



# **Global X MSCI China Consumer Discretionary ETF (CHIQ)**



#### **Targeted Exposure**

CHIQ is a targeted play on the Consumer Discretionary Sector in China - the world's second largest economy by GDP.



#### **ETF Efficiency**

CHIQ delivers access to dozens of consumer discretionary companies within the MSCI China Index, providing investors an efficient vehicle to express a sector view on China.



#### **All Share Exposure**

The Index incorporates China A, B and H shares, Red chips, P chips and foreign listings.

| Fund details       |             |           |              |
|--------------------|-------------|-----------|--------------|
| Inception date     | 30 Nov 2009 | Fund size | \$672.55 mil |
| Number of holdings | 79          | Exchange  | NYSE Arca    |

Source: Global X Management Company LLC as of 31 Mar 2021.

# Remark: Please study fund features, performance, and risk before investing. Past performance is not an indicative of future performance.

#### **INDUSTRY BREAKDOWN (%)**



<sup>\*</sup> Hotels/Resorts/Cruiselines 2.37%, Automotive Aftermarket 1.78%, Miscellaneous Commercial Services 1.70%, Electronics/Appliance Stores 1.04%, Medical/Nursing Services 0.99%, Apparel/Footwear Retail 0.70%, Home Furnishings 0.56%, Telecommunications Equipment 0.47%, Real Estate Development 0.29%, Wholesale Distributors 0.23%, Movies/ Entertainment 0.19%, Investment Banks/Brokers 0.10%, Electronic Production Equipment 0.09%, Department Stores 0.08%

#### TOP 10 HOLDINGS (%) Holdings Subject to Change

| Alibaba Grp-adr   | 9.75% | Yum China Holdings Inc   | 3.54% |
|-------------------|-------|--------------------------|-------|
| Meituan-class B   | 7.88% | Trip.com Group Ltd-adr   | 3.27% |
| Jd.com Inc-adr    | 7.54% | New Oriental-adr         | 3.06% |
| Nio Inc - Adr     | 5.73% | Anta Sports Products Ltd | 2.97% |
| Pinduoduo Inc-adr | 5.49% | Shenzhou Intl Gp         | 2.94% |


# Invesco China Technology ETF (CQQQ)

- The Invesco China Technology ETF is based on the FTSE China Incl A 25% Technology Capped Index
- The Index includes constituents of the FTSE China Index and FTSE China A Stock Connect Index that are classified as information technology securities, including China Ashares and China B-shares.

| Fund details       |            |                               |            |
|--------------------|------------|-------------------------------|------------|
| Inception date     | 8 Dec 2009 | P/B ratio                     | 8.36       |
| Number of holdings | 105        | P/E ratio                     | 30.97      |
| Exchange           | NYSE Arca  | Weighted market cap<br>(\$MM) | 390,233.77 |

Source: Invesco as of 31 Mar 2021.

#### Sector allocation (%)



| Top ETF holdings (%)        | (Total holdings: 105) |
|-----------------------------|-----------------------|
| Name                        | Weight                |
| Tencent                     | 10.30                 |
| Meituan 'B'                 | 8.85                  |
| Baidu ADR                   | 7.56                  |
| Sunny Optical Technology    | 7.43                  |
| Tencent Music Entertainme   | nt ADR 5.10           |
| Autohome ADR                | 4.28                  |
| Kingdee International Softw | are 4.07              |
| GDS ADR                     | 3.91                  |
| Kuaishou Technology         | 3.90                  |
| JOYY ADR                    | 3.50                  |



# **KraneShares MSCI China Clean Technology Index ETF (KGRN)**

# Five Key Clean Technology Themes of KGRN:



Source: KraneShares as of Mar 2021.



# **KraneShares MSCI China Clean Technology Index ETF (KGRN)**

| <b>Top 10 Holdings</b> as of 03/31/2021 Holdings are subject to change. | Ticker | %    |
|-------------------------------------------------------------------------|--------|------|
| CONTEMPORARY A-A                                                        | 300750 | 9.07 |
| NIO INC - ADR                                                           | NIO    | 7.88 |
| XINYI SOLAR HOLDINGS LTD                                                | 968    | 7.20 |
| CONCH VENTURE                                                           | 586    | 6.07 |
| BYD CO LTD-H                                                            | 1211   | 6.01 |
| SHIMAO GROUP HOLDINGS LTD                                               | 813    | 5.57 |
| CHINA EVERGRANDE GROUP                                                  | 3333   | 5.27 |
| XPENG INC - ADR                                                         | XPEV   | 4.87 |
| LONGI GREEN EN-A                                                        | 601012 | 4.27 |
| CHINA LONGYUAN-H                                                        | 916    | 4.04 |

| Sector Breakdown Data from Bloomberg as of 03/31/2021 | %     |
|-------------------------------------------------------|-------|
| Consumer Discretionary                                | 31.60 |
| Information Technology                                | 24.99 |
| Industrials                                           | 23.80 |
| Utilities                                             | 11.74 |
| Real Estate                                           | 7.75  |

| Fund details       |               |  |  |
|--------------------|---------------|--|--|
| Inception date     | 12 Oct 2017   |  |  |
| Number of holdings | 46            |  |  |
| Net Assets         | \$141,173,331 |  |  |
| Exchange           | NYSE          |  |  |

Source: KraneShares as of Mar 2021.



# KraneShares MSCI China Clean Technology Index ETF (KGRN)

# **Examples of fund holdings**

| Theme      |                         | Example constituent                  | Fund holding<br>weight<br>(as of 12/31/2020) | Company logo                       | Company Description                                                                                                                                                                                                                                                   |
|------------|-------------------------|--------------------------------------|----------------------------------------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|            | Alternative<br>Energy   | Xinyi Solar<br>Holdings Ltd          | 10.80%                                       | <b>Qxus</b> °                      | Xinyi Solar Holdings Limited manufactures renewable energy products.<br>The Company offers various types of solar glass and other related items.<br>Xinyi Solar Holdings serves customers worldwide.                                                                  |
| <b>(6)</b> | Sustainable<br>Water    | Beijing<br>Enterprise<br>Water       | 3.06%                                        | 北接水務集團有限公司                         | Beijing Enterprises Water Group Limited develops water treatment systems. The Group specializes in water services and environmental protection businesses, with waste water treatment as its core business segment.                                                   |
| •          | Green<br>Building       | Shimao<br>Property<br>Holdings Ltd   | 2.90%                                        | SHIM-<br>世茂房地产                     | Shimao Property Holdings Limited develops a diversified range of real estate projects in China. The Company focuses on residential, hotel, office, and commercial properties in cities with dynamic economic growth potential.                                        |
|            | Pollution<br>Prevention | China<br>Everbright<br>International | 3.16%                                        | 光大國際<br>Evertirizate International | China Everbright International Limited provides environmental protection project management and consultancy services. The Company's operations are broken up into environmental energy, environmental water, environmental construction and environmental technology. |
| <b>*</b>   | Energy<br>Efficiency    | Nio Inc.                             | 9.49%                                        | <b>⇔</b> NIO                       | NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.                                                                                           |

Source: Bloomberg, KraneShares as of 31 Dec 2020.



# KraneShares MSCI All China Health Care Index ETF (KURE)

KURE invests in Chinese companies that are involved in the healthcare industry, specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.













| <b>Top 10 Holdings</b> as of 03/31/2021 Holdings are subject to change. | Ticker | %    |
|-------------------------------------------------------------------------|--------|------|
| WUXI BIOLOGICS CAYMAN INC                                               | 2269   | 8.51 |
| JIANGSU HENGRU-A                                                        | 600276 | 6.04 |
| SHENZHEN MINDR-A                                                        | 300760 | 5.19 |
| BEIGENE LTD-ADR                                                         | BGNE   | 4.52 |
| WUXI APPTEC CO LTD-A                                                    | 603259 | 3.88 |
| CHONGQING ZHIF-A                                                        | 300122 | 3.38 |
| ALIBABA HEALTH                                                          | 241    | 3.12 |
| CSPC PHARMACEUTI                                                        | 1093   | 3.07 |
| AIER EYE HSPTL-A                                                        | 300015 | 3.04 |
| SINO BIOPHARMACEUTICAL                                                  | 1177   | 2.83 |

Source: KraneShares as of Mar 2021.



# KraneShares MSCI All China Health Care Index ETF (KURE)


# **Examples of fund holdings**

| Theme                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                       | Example<br>Holding | Holding weight<br>(as of 12/31/2020) | Company logo                            | Company Description                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|--------------------|--------------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ₽ <sub>k</sub>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Patent and Generic<br>Pharmaceuticals | Jiangsu Hengrui    | 7.45%                                | 恒瑞                                      | Jiangsu Hengrui develops, manufactures, and markets a variety of medicines and medicine packing materials. The Company specializes in the R&D of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Medical<br>Equipment<br>Production    | Shenzhen Mindray   | 5.43%                                | mindray                                 | Mindray is one of the leading global providers of medical devices and solutions in the fields of Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging System. Mindray is a leading ventilator manufacturer.                                                    |
| •                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Hospital<br>Administration            | Meinian Onehealth  | 0.56%                                | 美年大健康<br>Health IDD                     | Meinian Onehealth Healthcare Holdings Co., Ltd. provides health examinations, evaluations, consulting services and other medical services in 200+ medical facilities throughout China.                                                                                                 |
| The same of the sa | Biotechnology                         | WuXi Biologics     | 9.76%                                | WuXi Biologics Global Solution Provider | WuXi Biologics owns WuXi AppTec, a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. WuXi AppTec provides a portfolio of services throughout the drug R&D process.                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Traditional<br>Chinese Medicine       | Tong Ren Tang      | 0.40%                                | GOOREN S                                | Tong Ren Tang is a Chinese pharmaceutical company founded in 1669, which is now the largest producer of traditional Chinese medicine. The company is engaged in both manufacture and retail sales and drug store operations throughout China.                                          |
| <u>i</u>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Healthcare IT                         | Alibaba Healthcare | 3.25%                                | AliHealth<br>阿里健康                       | Ali Health provides internet solutions for the healthcare industry to increase cross-<br>regional sharing of existing social medicine resources and efficiencies of medical<br>treatment. AliHealth specializes in medical e-commerce, smart medical treatment and<br>product tracing. |

Source: Bloomberg, KraneShares as of 31 Dec 2020.



#### Portfolio simulation



Source: Morningstar as of 28 Feb 2021. Benchmark is MSCI China All Shares NR USD. Risk characteristics and returns are calculated based on portfolio simulation which is used for back test portfolio results of the proposed investment strategy, realized results may vary.



#### **Fund features**

| Details                                    | Krungsri China Megatrends fund-A (KFCMEGA-A) Risk level: 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Investment Policy                          | The fund will invest in units of foreign equity funds and/or Exchange Traded Funds (ETFs) which investment policy focuses on investment in listed securities in China and/or which main business or majority of revenue comes from business operations in China. These companies are related to beneficiaries of the rise of mega trends such as the growth of e-commerce, technological advancements, aging society or economic structural change in the future etc.  The fund will invest on average no less than 80% of its NAV in an accounting year in at least 2 funds and the exposure per each fund will not exceed 79% of NAV. The exposure in each foreign equity funds and/or ETFs will be upon fund manager's discretion which is subject to change based on market situation in each period. |
| FX Hedging Policy                          | Hedge against currency risk upon fund manager's discretion. Generally, the Fund will enter into a forward contract to hedge against the exchange rate risk on average of 90% of the foreign investment value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dealing Date                               | Daily (Please refer to Fund's Non-Dealing Calendar)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Settlement Date                            | T+3 (3 working days after the execution day excluding relevant Master Fund's holidays)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Minimum Investment Amount</b>           | 500 Baht                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dividend policy                            | The Accumulation share class has no dividend payment policy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Target investors                           | Suitable for ■ Investors who can accept fluctuation in price of stock in which the fund invests, which may increase or decrease to below the value of investment and thus resulting in loss. ■ Investors who able to make medium to long term investment, expecting better return in a long term than investment in fixed-income instruments.  Not suitable for: ■ Investors who need fixed return or principal protection                                                                                                                                                                                                                                                                                                                                                                                |
| Fee charge to the fund (% of NAV p.a.)     | Management fee : Not more than 2.1400% p.a. (Actual Charge: 1.0700%) Trustee fee : Not more than 0.1070% p.a. (Actual Charge: 0.0321%) Registrar fee : Not more than 0.1605% p.a. (Actual Charge: 0.1605%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Fee charge to investor (% of NAV per unit) | Front end fee or Switching-in fee : Not more than 2.00% p.a. (Actual Charge: 1.00%) Redemption fee or Switching-out fee: Not more than 2.00% p.a. (Actual Charge: None)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

All above mentioned fees include Value Added Tax or Specific Business Tax or other taxes • According to the fund's FX hedging policy, the fund may enter into a currency swap within discretion of fund manager which may incur exchange rate risk and investors may lose or gain from foreign exchange or receive lower return than the amount initially invested.



#### **Promotion**

# Every 100,000 Baht investment amount in Krungsri China Megatrends fund-A (KFCMEGA-A) during 7 – 15 June 2021

receive investment units of KFCMEGA-A value 100 Baht

#### Terms & Conditions:

- 1. This promotion is applicable to the NET investment amount in Krungsri China Megatrends fund-A (KFCMEGA-A) during IPO period only. Net investment amount means purchase or switching in value less redemption or switching out value.
- 2. Investors must hold units until 15 October 2021. The outstanding investment amount is based on the unit balance of the fund as of 15 June 2021. However, customers will not be eligible to join this promotion if they redeem and/or switch out investment units of the fund during 16 June 15 October 2021 regardless of the amount of redemption.
- 3. The Management Company will calculate the total investment amount in KFCMEGA-A based on each investor's unitholder account number. In case an investor has more than 1 account, the Management Company will not consolidate the total investment amount from all accounts for this promotion.
- 4. The total amount of investment amount, which is less than 100,000 Baht, will not be counted for the promotion.
- 5. The Management Company will allocate the promotion units of KFCMEGA-A to the eligible investors within 30 November 2021. The units of KFCMEGA-A will be calculated at its NAV price on the allocation date. Front-end fee is waived for the units of KFCMEGA-A received from this promotion.
- 6. Subscription and switch-in order through unit-linked life insurance is not eligible for this promotion.
- 7. Other terms and conditions may apply for the transaction executed through an omnibus account. Investor should contact your representative selling agents for further information.
- 8. Transferring units, either to the same or different investor, is not eligible for this promotion.
- 9. The Management Company reserves the right to offer other equivalent reward as appropriate or change terms & conditions of this promotion without prior notice.
- 10. This promotion expense is charged to the Management Company, not the fund.



#### **Disclaimer**

- 1. Krungsri Asset Management Co., Ltd. ("The Management Company") believes the information contained in this document is accurate at the time of publication but does not provide any warranty of its accuracy. Similarly, any opinions or estimates included herein constitute a judgment as of the time of publication. All information, opinions and estimates are subject to change without notice.
- 2. Krungsri China Megatrends fund A ("The fund") will invest in units of foreign equity funds and/or Exchange Traded Funds (ETFs) which investment policy focuses on investment in listed securities in China and/or which main business or majority of revenue comes from business operations in China. These companies are related to beneficiaries of the rise of mega trends such as the growth of e-commerce, technological advancements, aging society or economic structural change in the future etc. The fund will invest on average no less than 80% of its NAV in an accounting year in at least 2 funds and the exposure per each fund will not exceed 79% of NAV. The exposure in each foreign equity funds and/or ETFs will be upon fund manager's discretion which is subject to change based on market situation in each period.
- 3. The fund may enter into a currency swap within discretion of fund manager which may incur exchange rate risk and investors may lose or gain from foreign exchange or receive lower return than the amount initially invested.
- 4. The Fund may invest in non-investment grade or unrated securities in aggregate not exceeding 20% of NAV. Besides, the Fund may invest in unlisted securities and structured notes in accordance with the rules as specified by the SEC Office. Therefore, investors are subject to higher risk of not receiving their principal and interest payments that are due to them.
- 5. The Fund and/or the Master Fund may invest in forward contract to enhance efficiency portfolio management and structured note. This means the Fund may contain higher risks than other funds which invest directly in underlying assets. Therefore, it may have gain/loss higher than investing directly in underlying assets.
- 6. Before remitting in money, please carefully study fund features, performance, and risk. Past performance is not a guarantee of future results. For more details or to request for the Fund Prospectus, please contact:

Krungsri Asset Management Co., Ltd.

1<sup>st</sup> -2<sup>nd</sup> Zone A, 12<sup>th</sup> Floor, 18<sup>th</sup> Floor, Ploenchit Tower 898, Ploenchit Road, Lumpini, Pathumwan, Bangkok 10330 Tel: 02-657-5757 | E-mail: krungsriasset.mktg@krungsri.com | Website: www.krungsriasset.com



# Thank you